- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01306214
Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes Mellitus
May 16, 2014 updated by: Boehringer Ingelheim
A Phase III, Randomized, Double-blind, Placebo-controlled, Parallel Group Safety and Efficacy Study of BI 10773 (10 mg and 25 mg Administered Orally Once Daily) During 52 Weeks in Patients With Type 2 Diabetes Mellitus and Insufficient Glycemic Control on MDI Insulin Regimen Alone or With Metformin
This trial will evaluate use of BI 10773 as add-on to insulin regimen alone or with metformin in patients with typr 2 diabetes.
Both lowering glucose and HbA1c and reducing the use of insulin in this population would provide significant new information for the BI 10773 use and would offer a potential new therapeutic option in this population.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
566
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Bonheiden, Belgium
- 1245.49.32010 Boehringer Ingelheim Investigational Site
-
Edegem, Belgium
- 1245.49.32002 Boehringer Ingelheim Investigational Site
-
Huy, Belgium
- 1245.49.32007 Boehringer Ingelheim Investigational Site
-
Jette, Belgium
- 1245.49.32014 Boehringer Ingelheim Investigational Site
-
La Louvière, Belgium
- 1245.49.32013 Boehringer Ingelheim Investigational Site
-
Leuven, Belgium
- 1245.49.32012 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Pleven, Bulgaria
- 1245.49.59003 Boehringer Ingelheim Investigational Site
-
Sofia, Bulgaria
- 1245.49.59004 Boehringer Ingelheim Investigational Site
-
Stara Zagora, Bulgaria
- 1245.49.59001 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Barranquilla, Colombia
- 1245.49.57003 Boehringer Ingelheim Investigational Site
-
Bogota, Colombia
- 1245.49.57005 Boehringer Ingelheim Investigational Site
-
Bogota, Colombia
- 1245.49.57006 Boehringer Ingelheim Investigational Site
-
Bogotá, Colombia
- 1245.49.57004 Boehringer Ingelheim Investigational Site
-
Medellín, Colombia
- 1245.49.57002 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Breclav, Czech Republic
- 1245.49.42013 Boehringer Ingelheim Investigational Site
-
Brno, Czech Republic
- 1245.49.42003 Boehringer Ingelheim Investigational Site
-
Brno, Czech Republic
- 1245.49.42010 Boehringer Ingelheim Investigational Site
-
Chrudim, Czech Republic
- 1245.49.42011 Boehringer Ingelheim Investigational Site
-
Hodonin, Czech Republic
- 1245.49.42009 Boehringer Ingelheim Investigational Site
-
Svitavy56802, Czech Republic
- 1245.49.42012 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Kuopio, Finland
- 1245.49.72001 Boehringer Ingelheim Investigational Site
-
Oulu, Finland
- 1245.49.72002 Boehringer Ingelheim Investigational Site
-
Turku, Finland
- 1245.49.72003 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Grenoble Cedex, France
- 1245.49.33001 Boehringer Ingelheim Investigational Site
-
Le Creusot, France
- 1245.49.33011 Boehringer Ingelheim Investigational Site
-
Marseille, France
- 1245.49.33012 Boehringer Ingelheim Investigational Site
-
Nantes cedex 1, France
- 1245.49.33003 Boehringer Ingelheim Investigational Site
-
Narbonne Cedex, France
- 1245.49.33010 Boehringer Ingelheim Investigational Site
-
Pierre Benite, France
- 1245.49.33004 Boehringer Ingelheim Investigational Site
-
Point-à-Pitre Cedex, France
- 1245.49.33007 Boehringer Ingelheim Investigational Site
-
Saint Priest en Jarez, France
- 1245.49.33008 Boehringer Ingelheim Investigational Site
-
Vénissieux Cedex, France
- 1245.49.33009 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Bosenheim, Germany
- 1245.49.49104 Boehringer Ingelheim Investigational Site
-
Dresden, Germany
- 1245.49.49013 Boehringer Ingelheim Investigational Site
-
Mainz, Germany
- 1245.49.49101 Boehringer Ingelheim Investigational Site
-
Neuwied, Germany
- 1245.49.49002 Boehringer Ingelheim Investigational Site
-
Saarbrücken, Germany
- 1245.49.49005 Boehringer Ingelheim Investigational Site
-
Wangen, Germany
- 1245.49.49102 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Guatemala, Guatemala
- 1245.49.50201 Boehringer Ingelheim Investigational Site
-
Guatemala, Guatemala
- 1245.49.50202 Boehringer Ingelheim Investigational Site
-
Guatemala, Guatemala
- 1245.49.50203 Boehringer Ingelheim Investigational Site
-
Guatemala, Guatemala
- 1245.49.50204 Boehringer Ingelheim Investigational Site
-
Quetzaltenango, Guatemala
- 1245.49.50205 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Aguascalientes, Mexico
- 1245.49.52011 Boehringer Ingelheim Investigational Site
-
Cuautla, Mexico
- 1245.49.52012 Boehringer Ingelheim Investigational Site
-
Durango, Mexico
- 1245.49.52003 Boehringer Ingelheim Investigational Site
-
Durango, Mexico
- 1245.49.52005 Boehringer Ingelheim Investigational Site
-
Guadalajara, Mexico
- 1245.49.52004 Boehringer Ingelheim Investigational Site
-
Guadalajara, Mexico
- 1245.49.52006 Boehringer Ingelheim Investigational Site
-
Guadalajara, Mexico
- 1245.49.52008 Boehringer Ingelheim Investigational Site
-
Monterrey, Mexico
- 1245.49.52002 Boehringer Ingelheim Investigational Site
-
Monterrey, Mexico
- 1245.49.52009 Boehringer Ingelheim Investigational Site
-
Monterrey, Mexico
- 1245.49.52010 Boehringer Ingelheim Investigational Site
-
México, D.F., Mexico
- 1245.49.52001 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Arequipa, Peru
- 1245.49.51002 Boehringer Ingelheim Investigational Site
-
Arequipa, Peru
- 1245.49.51006 Boehringer Ingelheim Investigational Site
-
Jesus Maria, Peru
- 1245.49.51010 Boehringer Ingelheim Investigational Site
-
Lima, Peru
- 1245.49.51001 Boehringer Ingelheim Investigational Site
-
Lima, Peru
- 1245.49.51008 Boehringer Ingelheim Investigational Site
-
Lima, Peru
- 1245.49.51009 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Moscow, Russian Federation
- 1245.49.70008 Boehringer Ingelheim Investigational Site
-
Moscow, Russian Federation
- 1245.49.70009 Boehringer Ingelheim Investigational Site
-
St. Petersburg, Russian Federation
- 1245.49.70006 Boehringer Ingelheim Investigational Site
-
St. Petersburg, Russian Federation
- 1245.49.70010 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Avila, Spain
- 1245.49.34039 Boehringer Ingelheim Investigational Site
-
MBoadilla del Monte (Madrid), Spain
- 1245.49.34043 Boehringer Ingelheim Investigational Site
-
Madrid, Spain
- 1245.49.34038 Boehringer Ingelheim Investigational Site
-
Madrid, Spain
- 1245.49.34044 Boehringer Ingelheim Investigational Site
-
Palma de Mallorca, Spain
- 1245.49.34047 Boehringer Ingelheim Investigational Site
-
Santiago de Compostela (La Coruña), Spain
- 1245.49.34016 Boehringer Ingelheim Investigational Site
-
Valencia, Spain
- 1245.49.34041 Boehringer Ingelheim Investigational Site
-
pozuelo de Alarcon, Spain
- 1245.49.34045 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Kharkov, Ukraine
- 1245.49.75016 Boehringer Ingelheim Investigational Site
-
Kiev, Ukraine
- 1245.49.75007 Boehringer Ingelheim Investigational Site
-
Kiev, Ukraine
- 1245.49.75014 Boehringer Ingelheim Investigational Site
-
Kiev, Ukraine
- 1245.49.75015 Boehringer Ingelheim Investigational Site
-
Kyiv, Ukraine
- 1245.49.75013 Boehringer Ingelheim Investigational Site
-
-
-
-
Alabama
-
Birmingham, Alabama, United States
- 1245.49.10005 Boehringer Ingelheim Investigational Site
-
-
Arizona
-
Chandler, Arizona, United States
- 1245.49.10011 Boehringer Ingelheim Investigational Site
-
Tucson, Arizona, United States
- 1245.49.10004 Boehringer Ingelheim Investigational Site
-
-
California
-
Corona, California, United States
- 1245.49.10002 Boehringer Ingelheim Investigational Site
-
El Cajon, California, United States
- 1245.49.10013 Boehringer Ingelheim Investigational Site
-
Lomita, California, United States
- 1245.49.10030 Boehringer Ingelheim Investigational Site
-
Spring Valley, California, United States
- 1245.49.10014 Boehringer Ingelheim Investigational Site
-
Westlake Village, California, United States
- 1245.49.10019 Boehringer Ingelheim Investigational Site
-
-
Colorado
-
Denver, Colorado, United States
- 1245.49.10024 Boehringer Ingelheim Investigational Site
-
-
Florida
-
Hialeah, Florida, United States
- 1245.49.10018 Boehringer Ingelheim Investigational Site
-
Miami, Florida, United States
- 1245.49.10016 Boehringer Ingelheim Investigational Site
-
-
Georgia
-
Blue Ridge, Georgia, United States
- 1245.49.10021 Boehringer Ingelheim Investigational Site
-
-
Illinois
-
Chicago, Illinois, United States
- 1245.49.10009 Boehringer Ingelheim Investigational Site
-
-
Indiana
-
Evansville, Indiana, United States
- 1245.49.10015 Boehringer Ingelheim Investigational Site
-
-
North Carolina
-
Greenville, North Carolina, United States
- 1245.49.10023 Boehringer Ingelheim Investigational Site
-
-
North Dakota
-
Fargo, North Dakota, United States
- 1245.49.10007 Boehringer Ingelheim Investigational Site
-
-
Ohio
-
Columbus, Ohio, United States
- 1245.49.10006 Boehringer Ingelheim Investigational Site
-
-
South Carolina
-
Greer, South Carolina, United States
- 1245.49.10025 Boehringer Ingelheim Investigational Site
-
-
Tennessee
-
Memphis, Tennessee, United States
- 1245.49.10022 Boehringer Ingelheim Investigational Site
-
-
Texas
-
Austin, Texas, United States
- 1245.49.10003 Boehringer Ingelheim Investigational Site
-
Dallas, Texas, United States
- 1245.49.10001 Boehringer Ingelheim Investigational Site
-
Houston, Texas, United States
- 1245.49.10031 Boehringer Ingelheim Investigational Site
-
-
Utah
-
Bountiful, Utah, United States
- 1245.49.10033 Boehringer Ingelheim Investigational Site
-
Salt Lake City, Utah, United States
- 1245.49.10032 Boehringer Ingelheim Investigational Site
-
-
Virginia
-
Norfolk, Virginia, United States
- 1245.49.10026 Boehringer Ingelheim Investigational Site
-
-
Washington
-
Renton, Washington, United States
- 1245.49.10020 Boehringer Ingelheim Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion criteria:
- Diagnosis of T2DM prior to informed consent
- Male and female patients on diet and exercise regimen who are pre-treated with multiple daily injections (MDI) of insulin alone or in combination with immediate or extended release metformin
- Stable metformin therapy: daily dose >=1500 mg/day or maximum tolerated dose
- HbA1c >=7.5% and <=10% at screening
Exclusion criteria:
- Uncontrolled hyperglycemia with a glucose level >240 mg/dl (>13.3 mmol/L) after an overnight fast during placebo run-in
- Any contraindications to metformin according to the local label
- Acute coronary syndrome, stroke or TIA within 3 months prior to informed consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: Placebo
Placebo tablets matching BI 10773
|
Placebo matching BI 10773 low dose
Placebo matching BI 10773 high dose
|
EXPERIMENTAL: BI 10773 low dose
BI 10773 low dose once daily
|
Placebo matching BI 10773 low dose
BI 10773 high dose once daily
BI 10773 low dose once daily
Placebo matching BI 10773 high dose
|
EXPERIMENTAL: BI 10773 high dose
BI 10733 high dose once daily
|
Placebo matching BI 10773 low dose
BI 10773 high dose once daily
BI 10773 low dose once daily
Placebo matching BI 10773 high dose
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in HbA1c After 18 Weeks of Treatment
Time Frame: Baseline and 18 weeks
|
The primary endpoint was the change from baseline in HbA1c after 18 weeks of treatment.
|
Baseline and 18 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Insulin Dose After 52 Weeks of Treatment
Time Frame: Baseline and 52 weeks
|
The secondary endpoint is change from baseline in insulin dose after 52 weeks of treatment
|
Baseline and 52 weeks
|
Change From Baseline in Body Weight After 52 Weeks of Treatment
Time Frame: Baseline and 52 weeks
|
The secondary endpoint was the change from baseline in body weight after 52 weeks of treatment
|
Baseline and 52 weeks
|
Change From Baseline in HbA1c After 52 Weeks of Treatment
Time Frame: Baseline and 52 weeks
|
The secondary endpoint was the change from baseline in HbA1c after 52 weeks of treatment
|
Baseline and 52 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Tuttle KR, Levin A, Nangaku M, Kadowaki T, Agarwal R, Hauske SJ, Elsasser A, Ritter I, Steubl D, Wanner C, Wheeler DC. Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials. Diabetes Care. 2022 Jun 2;45(6):1445-1452. doi: 10.2337/dc21-2034.
- Rosenstock J, Jelaska A, Frappin G, Salsali A, Kim G, Woerle HJ, Broedl UC; EMPA-REG MDI Trial Investigators. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care. 2014 Jul;37(7):1815-23. doi: 10.2337/dc13-3055. Epub 2014 Jun 14.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2011
Primary Completion (ACTUAL)
April 1, 2013
Study Completion (ACTUAL)
April 1, 2013
Study Registration Dates
First Submitted
February 28, 2011
First Submitted That Met QC Criteria
February 28, 2011
First Posted (ESTIMATE)
March 1, 2011
Study Record Updates
Last Update Posted (ESTIMATE)
June 17, 2014
Last Update Submitted That Met QC Criteria
May 16, 2014
Last Verified
May 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1245.49
- 2010-019968-37 (EUDRACT_NUMBER: EudraCT)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Fundació Sant Joan de DéuNot yet recruitingObesity, Childhood | Obesity, AdolescentSpain
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States